Improved efficacy of a dendritic cell-based vaccine against a murine model of colon cancer: The helper protein effect

Cancer Research and Treatment

Volumn 47, Issue 3, 2015, Pages 518-526

  Zarnani, Amir Hassan ^a,b   Torabi Rahvar, Monireh ^b   Bozorgmehr, Mahmood ^a   Zareie, Mehri ^c   Mojtabavi, Nazanin ^b  

^a AVICENNA RESEARCH INSTITUTE   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Independent Consultant   (Canada)

Author keywords

Dendritic cells; Helper protein; Immunotherapy; Neoplasms; Vaccination

Indexed keywords

AH1 PEPTIDE; DENDRITIC CELL VACCINE; OVALBUMIN; PROTEIN P15; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER SIZE; CANCER SURVIVAL; CANCER TISSUE; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; EX VIVO STUDY; IMMUNOFLUORESCENCE; IN VITRO STUDY; MOUSE; NONHUMAN; SPLEEN CELL; SURVIVAL RATE; WESTERN BLOTTING;

EID: 84937117477     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2013.241     Document Type: Article

References (24)

1. Voss CY, Albertini MR, Malter JS. Dendritic cell-based immunotherapy for cancer and relevant challenges for transfusion medicine. Transfus Med Rev. 2004;18:189-202.
2. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12:265-77.
3. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12:269-81.
4. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278-87.
5. Aptsiauri N, Cabrera T, Garcia-Lora A, Garrido F. Cancer immune escape: implications for immunotherapy, Granada, Spain, October 3-5, 2011. Cancer Immunol Immunother. 2012;61:739-45.
6. Torabi-Rahvar M, Bozorgmehr M, Jeddi-Tehrani M, Zarnani AH. Potentiation strategies of dendritic cell-based antitumor vaccines: combinational therapy takes the front seat. Drug Discov Today. 2011;16:733-40.
7. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12:237-51.
8. Shimizu K, Thomas EK, Giedlin M, Mule JJ. Enhancement of tumor lysate-and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res. 2001;61:2618-24.
9. Timmerman JM, Levy R. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J Immunol. 2000;164:4797-803.
10. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99:1517-26.
11. Millard AL, Ittelet D, Schooneman F, Bernard J. Dendritic cell KLH loading requirements for efficient CD4+ T-cell priming and help to peptide-specific cytotoxic T-cell response, in view of potential use in cancer vaccines. Vaccine. 2003;21:869-76.
12. Shojaeian J, Jeddi-Tehrani M, Dokouhaki P, Mahmoudi AR, Ghods R, Bozorgmehr M, et al. Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously. J Immunother. 2009;32:325-32.
13. Casares N, Lasarte JJ, de Cerio AL, Sarobe P, Ruiz M, Melero I, et al. Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol. 2001;31:1780-9.
14. Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, Schmidt SM, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006;66:5910-8.
15. Zarnani AH, Shahbazi M, Salek-Moghaddam A, Zareie M, Tavakoli M, Ghasemi J, et al. Vitamin D3 receptor is expressed in the endometrium of cycling mice throughout the estrous cycle. Fertil Steril. 2010;93:2738-43.
16. Shojaeian S, Allameh A, Zarnani AH, Chamankhah M, Ghods R, Bayat AA, et al. Production and characterization of monoclonal antibodies against the extracellular domain of CA 125. Immunol Invest. 2010;39:114-31.
17. Shahbazi M, Jeddi-Tehrani M, Zareie M, Salek-Moghaddam A, Akhondi MM, Bahmanpoor M, et al. Expression profiling of vitamin D receptor in placenta, decidua and ovary of pregnant mice. Placenta. 2011;32:657-64.
18. Zarnani AH, Moazzeni SM, Shokri F, Salehnia M, Dokouhaki P, Shojaeian J, et al. The efficient isolation of murine splenic dendritic cells and their cytochemical features. Histochem Cell Biol. 2006;126:275-82.
19. Zarnani AH, Moazzeni SM, Shokri F, Salehnia M, Dokouhaki P, Ghods R, et al. Microenvironment of the feto-maternal interface protects the semiallogenic fetus through its immunomodulatory activity on dendritic cells. Fertil Steril. 2008;90:781-8.
20. Mimura Y, Mimura-Kimura Y, Doores K, Golgher D, Davis BG, Dwek RA, et al. Folding of an MHC class II-restricted tumor antigen controls its antigenicity via MHC-guided processing. Proc Natl Acad Sci U S A. 2007;104:5983-8.
21. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2012;30:1-22.
22. Eriksson K, Sun JB, Nordstrom I, Fredriksson M, Lindblad M, Li BL, et al. Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class Irestricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor. Eur J Immunol. 2004;34:1272-81.
23. Eriksson K, Fredriksson M, Nordstrom I, Holmgren J. Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development. Infect Immun. 2003;71:1740-7.
24. George-Chandy A, Eriksson K, Lebens M, Nordstrom I, Schon E, Holmgren J. Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells. Infect Immun. 2001;69:5716-25.